Join Growin Stock Community!

Artelo biosciences, inc.ARTL.US Overview

US StockHealthcare
(No presentation for ARTL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ARTL AI Insights

ARTL Overall Performance

ARTL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ARTL Recent Performance

-2.94%

Artelo biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ARTL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ARTL Key Information

ARTL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ARTL Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Price of ARTL

ARTL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ARTL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.50
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.50
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ARTL's latest earnings report released?

    The most recent financial report for Artelo biosciences, inc. (ARTL) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ARTL's short-term business performance and financial health. For the latest updates on ARTL's earnings releases, visit this page regularly.

  • How much debt does ARTL have?

    As of the end of the reporting period, Artelo biosciences, inc. (ARTL) had total debt of 678K, with a debt ratio of 0.24. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ARTL have?

    At the end of the period, Artelo biosciences, inc. (ARTL) held Total Cash and Cash Equivalents of 600K, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ARTL's EPS continuing to grow?

    According to the past four quarterly reports, Artelo biosciences, inc. (ARTL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.04. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ARTL?

    Artelo biosciences, inc. (ARTL)'s Free Cash Flow (FCF) for the period is -2.91M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 13.4% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ARTL?

    The latest valuation data shows Artelo biosciences, inc. (ARTL) has a Price-To-Earnings (PE) ratio of -0.21 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.